OncoDNA will begin early‑access roll‑out of OncoXplore, a fragmentomics‑based cell‑free DNA sequencing assay, to research and early access customers while pursuing CE‑IVDR certification for broader diagnostic use. The assay analyzes cfDNA fragmentation patterns to support therapy selection, tissue‑of‑origin determinations, and potential MRD monitoring; it was co‑developed with KU Leuven as part of a €12 million European initiative. OncoDNA has deployed OncoXplore at seven European sequencing centers and is validating the test across academic partners; the company positions the assay initially for therapy selection and cancer‑of‑unknown‑primary cases where fragmentomics can inform tissue origin. OncoDNA acknowledged that tumor‑informed MRD assays maintain higher analytical sensitivity but pitched OncoXplore as a versatile, sequencing‑based option for multiple clinical contexts.